ArticleJAMA network open2020
Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial.
Zhijie Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
37 papers cite it
this paperpooled ittrialcites it